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Abstract 
Review on SYK, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Identity 
Other names: P72-Syk 
HGNC (Hugo): SYK 
Location: 9q22.2 
DNA/RNA 
Description 
The spleen tyrosine kinase (SYK) gene encodes a 
member of the family of non-receptor type Tyr 
protein kinases (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=SYK). The cDNA clone 
encoding porcine SYK was identified by Taniguchi 
et al (Taniguchi 1991; Yamada 1993), and thereafter 
the SYK cDNA for mouse and human, respectively, 
was cloned (Hutchcroft 1991; Hutchcroft 1992; 
Müller 1994; Ku 1994). Initially, a smaller porcine 
SYK protein product was purified and was found to 
be proteolytically cleaved from  
the mature SYK protein (Kobayashi 1990). The 
PTK72 was at the same time found to be identical 
with the cloned SYK (LePrince 1993; Law 1994). 
Transcription 
The transcript encodes 635 amino acids with a mass 
of 72,066 Da. Two isoforms have been described, 
isoform long (L) and isoform short (S) 
(http://www.uniprot.org/uniprot/P43405): Isoform 1 
(full-length); Isoform 2 (283-305 missing) 
Protein 
Description 
SYK is a 72 kDa non-receptor type protein tyrosine 
kinase (PTK) that contains two SRC homology 2 
(SH2) domains, interdomains A and B, and a C-
terminal kinase domain (Fig. 2). SYK was initially 
shown to be expressed in lymphocytes and 
associated with the IgM and IgD receptor complexes 
in B cells (Taniguchi 1991; Hutchcroft 1992). The 
requirement for Src-PTKs associated with the B cell 
receptor (BCR) for phosphorylation of SYK was 
investigated early, and was shown to enhance the 
activity of SYK (Kurosaki 1994). 
Figure 1. Mapping of SYK gene on chromosome 9q22.2 (from GeneCards Syk gene). 
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Figure 2. Schematic structure of spleen tyrosine kinase (SYK) protein (adopted from Pamuk et al 2010). The protein includes two 
tandem SH2 domains and a tyrosine kinase domain. Between the two SH2 domains is interdomain A while interdomain B is 
located between the tyrosine kinase domain and C-terminal domain. ITAM, immunoreceptor tyrosine-based activation motif; 
SH2, Src homology 2. 
 
The PTK ZAP70 was cloned in T lymphocytes and 
shown to be homologous to SYK (Chan 1992). An 
alternatively spliced form of SYK also exists, 
missing 23 amino acids from interdomain A (Sada 
2001). The topology of the N-terminal part of SYK 
is similar to its counterpart ZAP70 as revealed by the 
crystal structure (Narula 1995; Hatada 1995). In 
1998, Fütterer et al presented the crystal structure of 
the tandem SH2 domain of SYK complexed with a 
dually phosphorylated ITAM peptide (Fütterer 
1998). The tandem SH2 domains selectively bind to 
diphosphorylated immunoreceptor tyrosine based 
activating motifs (ITAM) of the cytoplasmic region 
of the BCR (Sada 2001). The crystal structure of a 
full-length version of ZAP70 has given a greater 
understanding of the activation process for both 
SYK and Zap-70 (Deindl 2007). 
Atwell et al determined the structure of the 
unphosphorylated form of the SYK kinase catalytic 
domain (SYK-KD) in order to understand the 
molecular mechanism responsible for its enzymatic 
activity (Atwell 2004). The SYK kinase domain has 
a subdomain structure composed of a largely β-sheet 
N-terminal lobe, a largely α–helical C-terminal lobe, 
with the active site being sandwiched between the 
two lobes. The N-terminal lobe consists of a five-
stranded β -sheet plus a single α –helix. The larger 
C-terminal lobe is predominantly α –helical with 
three short β -strands: one at the hinge region and 
two between the activation loop and the main body 
of the C-lobe. From the structure of the SYK kinase 
domain it was deduced that the SYK catalytic 
activity does not require activation loop 
phosphorylation. 
SYK have multiple sites of phosphorylation which 
both regulate activity and serve as docking motifs for 
other proteins (Sada 2001). Phosphorylation sites 
include Tyr-348 and Tyr-352 within the SH2-linker 
region (Brdicka 2005), Tyr-525 and Tyr-526 within 
the activation loop of the kinase domain (Zhang 
2000), Tyr-630 in the C terminus of SYK, and others 
(Kulathu 2008; Tsang 2008; and reviewed by Sada 
2001). In B cells, the phosphorylation of two 
tyrosines within the ITAM leads to the physical 
recruitment of SYK to the site of the clustered 
receptor in an interaction mediated by its tandem pair 
of SH2 domains (reviewed in Geahlen 2009). 
Shortly following BCR engagement, SYK that has 
been recruited to the receptor becomes 
phosphorylated on multiple tyrosines through both 
autophosphorylation and phosphorylation by Lyn. 
Expression 
SYK expression in hematopoietic cells has been 
extensively determined by studying SYK as an 
effector of BCR signalling. Turner and co-workers 
found that after BCR activation, SYK-dependent 
signaling pathways regulate the clonal expansion, 
differentiation, or apoptosis of B cells (Turner 2000). 
Most of the cells of the hematopoietic system 
express SYK, but the PTK is also expressed at lower 
levels in some epithelial cells, fibroblasts, 
hepatocytes, vascular smooth muscle cells, 
endothelial cells and neuronal cells where it 
mediates various responses including adipogenesis, 
cell division, tumor suppression, ERK activation and 
neuronal differentiation (Turner 2000; Yanagi 2001; 
Zhou 2006; Tohyama 2009; Geahlen 2009; Mócsai 
2010; Krisenko 2015). 
In hepatocytes, after the use of the SYK-selective 
inhibitor piceatannol, it was indicated that SYK is 
necessary for mitogen activated protein kinase 
(MAPK) activation by G-protein coupled receptors 
in this cell type (Tsuchida 2000). Additionally, SYK 
expression has also been observed in normal human 
breast tissue, benign lesions and low-tumourigenic 
breast cancer cell lines (Coopman 2000). 
Localisation 
SYK is an intracellular PTK, known to function at 
the plasma membrane, where the receptors to which 
it is recruited are located (Zhou 2006). In lymphoid 
and epithelial cells, SYK has been found to reside in 
both the nucleus and cytoplasm (Ma 2001; Wang 
2003; Wang 2004). The expression and localization 
of SYK in the nucleus of breast cancer cells have 
been correlated with the repression of invasive tumor 
growth (Wang 2003). 
Function 
The SYK protein is known to have an important role 
in adaptive immune receptor signalling with recent 
reports indicating its mediation of other diverse 
biological functions, including cellular adhesion, 
innate immune recognition, osteoclast maturation, 
platelet activation and vascular development 
(Mócsai 2010). The protein is also involved in 
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coupling activated immunoreceptors to downstream 
signaling events that mediate diverse cellular 
responses, including proliferation, differentiation, 
and phagocytosis. 
SYK plays a critical role in the transition of pro-B 
cells into pre-B cells (Turner 1995). SYK is greatly 
involved in signal transduction initiated by the 
classic immunoreceptors, including BCRs, Fc 
receptors, and the activating natural killer receptors 
(Tohyama 2009; Berton 2005; Crowley 1997). SYK 
is associated mainly with ITAM dependent pathways 
and affects early development and activation of 
various cells including B cells, mast cell 
degranulation, neutrophil and macrophage 
phagocytosis, as well as platelet activation (Zhou 
2006; Tohyama 2009; Mócsai 2010). SYK-mediated 
phosphorylation of various adaptor proteins leads to 
the activation of downstream pathways that execute 
phagocytosis. SYK is important in complement-
mediated phagocytosis resulting from the binding of 
C3bi-coated particles to complement receptor 3 
(Tohyama 2009; Tohyama 2006). SYK is known to 
play a major role in the development of signal 
transduction events initiated after high-affinity IgE 
receptor (FCER1A) aggregation (Wong 2004; 
Matsubara 2006), mast cell activation, 
degranulation, and cytokine production (Matsubara 
2006; Masuda 2008). It is anticipated that SYK 
activation coupled with platelet activation and 
aggregation may assist in lymphatic vessel 
development and their separation from blood vessels 
(Mócsai 2010, Turner 1995). SYK is claimed to have 
a role in osteoclast differentiation and osteoclast 
function (Tohyama 2009, Mócsai 2010). SYK has 
been found to have a major role in pre T-cell receptor 
(TCR) signalling. This is known to occur during the 
transition from the double negative 3 (DN3) to the 
DN4 stage of early thymocyte development 
(Palacios 2007). In vivo studies have shown that 
SYK is required for firm leukocyte adhesion to 
inflamed endothelium (Frommhold 2007) and 
development of vasculopathy reaction (Hirahashi 
2006). The innate immune system uses pattern 
recognition receptors (PRRs) to detect pathogen-
associated molecular patterns (PAMPs) and activate 
immune responses. SYK has been found to be a key 
component of these pathways and increased 
evidence points to the involvement of SYK-coupled 
PRRs in innate recognition of bacteria, with 
CLEC7A, CLEC6A and CLEC4E all implicated in 
sensing of mycobacterial PAMPs (Geijtenbeek 
2009). SYK is presumably also involved in 
signalling PRR-mediated recognition of certain 
viruses. 
The role of ZAP70 in B cells have been investigated, 
but is poorly understood possibly due to the 
functional redundancy between SYK and ZAP70 
(Fallah-Arani 2008). Toyabe et al displayed the 
ability of a T cell subpopulation to express high 
levels of SYK and partially compensate for loss of 
T-cell functions in patients with deficiency of 
ZAP70 (Toyabe 2001). 
Homology 
Both ZAP-70 and SYK are dependent upon a Src-
family protein tyrosine kinase for association with 
the phosphorylated zeta-chain. Thus, the differential 
expression of these kinases suggests the possibility 
of different roles for ZAP70 and SYK in TCR 
signaling and thymic development (Palacios 2007). 
Activation of PTKs is an important mechanism in the 
transduction of signals from multi-subunit 
immunoreceptors, including the B and T cell 
receptors for antigen and the widely distributed 
receptors for the Fc portion of immunoglobulins 
(Paolini 2001). ZAP70 is expressed in T cells, 
natural killer cells and thymocytes, whereas SYK is 
present in all hematopoietic cells. Both ZAP70 and 
SYK are reported to be activated after TCR 
stimulation.  
Nonetheless, ZAP70 activation is known to require 
presence of Lck or another associated Src family 
PTK, while SYK is independent of Lck to undergo 
phosphorylation (Chan 1994, Couture 1994, 
Kolanus 1993). Regardless of its presence in all 
thymocyte subsets, SYK expression is 
downregulated three- to fourfold in peripheral T 
cells and, contrary to ZAP70, SYK expression is 12- 
to 15-fold higher in peripheral B cells compared to 
peripheral T cells (Chan 1994). 
Another study showed functional homology in 
antigen receptor signaling by demonstrating that 
expression of ZAP70 in SYK-B cells reconstitutes 
BCR function (Kong 1995). Another feature that 
distinguish ZAP70 from SYK is its greater 
dependency on Src kinases for activation and its 
ability to phosphorylate and promote the auto-
activation of the downstream MAPK p38 (reviewed 
in Au-Yeung 2009). 
Mutations 
The development of B cells proceeds through a well-
characterized set of stages defined by the extent of 
antigen receptor rearrangement and the expression of 
particular cell surface markers. When mice deficient 
for recombination-activating gene 1 (RAG1) were 
reconstituted with fetal liver from SYK-deficient 
embryos, the pool of pre-B cells formed was 
reduced. This suggests that SYK is required for the 
proper signalling from the pre-BCR to generate or 
maintain the pool of pre-B cells. Indeed, it has been 
shown that SYK is an essential transducer of BCR 
signals required for the transition of immature into 
recirculating B cells (Turner 2000). Moreover, SYK-
deficient mice die due to embryonic and perinatal 
death (Turner 1995; Cheng 1995). 
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Epigenetics 
SYK can also be inactivated by epigenetic 
modifications (i.e. hypermethylation) 
Implicated in 
t(5;9)(q33;q22) 
Disease 
found in Peripheral T-cell lymphoma (Streubel et al. 
2006). 
Hybrid/Mutated gene 
N-terminal ITK (bp 1-577) fused in frame with C-
terminal SYK cDNA 
t(9;12)(q22;p12) 
Disease 
found in a case of myelodysplastic syndrome (Kuno 
et al. 2001). 
Oncogenesis 
ETV6-SYK is constituvely tyrosine phosphorylated 
Breast cancer 
SYK mRNA and protein expression in a panel of 
well-characterized breast cancer cell lines, normal 
mammary gland tissue, and a normal breast 
epithelial cell line has been investigated by 
Coopman et al (Coopman 2000). They readily 
detected SYK expression in normal mammary tissue 
and epithelium, as well as in non-invasive breast 
carcinoma cell lines. SYK expression was however 
observed to be reduced or absent in the invasive 
breast tumor cell lines. Hypermethylation of the 
SYK locus during breast cancer progression was 
found to cause a loss of SYK protein expression in 
highly invasive and metastatic human mammary 
carcinomas (Coopman 2000,Yuan 2001). Moreover, 
Wang et al have shown that full-length SYK can 
enter the nucleus and thereby suppress invasion 
(Wang 2003). The sequences confined to a region of 
the SYK molecule near the junction of the linker B 
and catalytic domain were determined to be 
responsible for its distribution between the nucleus 
and cytoplasm (Zhou 2006). It was further 
demonstrated that the distribution of SYK between 
the nucleus and cytoplasm was regulated by signals 
sent downstream from the activated BCR and require 
the receptor-mediated activation of protein kinase C 
(PKC) and the induction of new protein synthesis. 
Colon carcinoma 
Expression of the SYK gene in human colon 
carcinoma cells is known to be suppressed in a p53-
dependent manner, an indication that loss of p53 
function during tumorigenesis can lead to  
deregulation of SYK activity (Okamura 1999). As 
reviewed recently by Krisenko et al,the levels of 
SYK mRNA in many cancerous tissues, including 
colon, are higher than in normal corresponding tissue 
(Krisenko 2015). 
Gastric cancer 
An inverse correlation between nuclear SYK and 
lymph node metastasis was observed in gastric 
cancer patients (Wang 2004). 
Ovarian cancer 
Ovarian tumors of low malignant grade have low 
levels of SYK compared to aggressive grades, which 
have the highest levels (Prinos 2011). Interestingly, 
when SYK expression was silenced, anchorage-
independent growth was inhibited, and apoptosis 
was induced in SYK-expressing ovarian cancer 
cells. 
Lung cancer 
Primary tumors of small cell lung cancer (SCLC) 
was examined and found to express higher levels of 
SYK compared to normal alveolar epithelium 
(reviewed by Krisenko 2015). 
Chronic lymphocytic leukemia (CLL) 
Both SYK and ZAP70 are present in CLL in B cells 
and may compete in facilitating BCR signaling 
(reviewed in Au-Yeung 2009). CLL fall into two 
classes, an indolent milder form and an aggressive 
form that is particularly dependent on SYK activity 
for survival (Buchner 2009). 
Diffuse large B-cell lymphoma 
(DLBCL) 
DLBCL can exhibit tonic or chronic signaling from 
the BCR that results in constitutive phosphorylation 
of SYK on activation loop tyrosines (Chen 2008). In 
a study from 2011 by Cheng et al, 44% of DLBCL 
samples showed elevated levels of phosphorylated 
SYK (Cheng 2011). 
Follicular lymphoma (FL) 
Constitutive activation of SYK has been reported in 
FL, were primary cells are hyperresponsive to BCR 
engagement as compared to nonmalignant B cells 
(Leseux 2006; Irish 2006). 
Mantle cell lymphoma (MCL) 
Constitutive activation of SYK has been reported in 
MCL as well, with a frequent overexpression of 
SYK due to gene amplification in both cell lines and 
primary tumors (Rinaldi 2006). 
Marginal zone lymphoma  (MZL) 
Ruiz-Ballesteros reported upregulation of SYK in 
splenic MZL, potentially due to downregulation of 
microRNAs predicted to modulate SYK gene 
transcription (Ruiz-Ballesteros 2005). 
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B cell acute lymphocytic leukemia (B-
ALL) 
B-ALL cells are derived from pro-B cells that lack 
pre-BCR or BCR complexes, but still these cells 
have elevated levels of constitutively active 
phosphorylated SYK (Perova 2014). 
Rheumatoid arthritis (RA) 
It is likely that SYK is widely expressed in a range 
of haemopoietic cell lineages in RA synovium. 
Inhibition of Syk suppresses both inflammation and 
bone erosion in animal models of RA (Singh Najjar 
2014). Indeed, Syk has been shown to be necessary 
for emerging pathology in several animal models of 
arthritis. 
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